Synthesis and Evaluation of New Bis‐1,3,4,2‐triazaphospholinoalkane Derivatives as In Vitro α‐Amylase and Lipase Inhibitors

Abstract

A series of new 1,ω-bis-(5-alkyl-2-oxide-3-tosyl-1,3,4,2-triazaphospholino)alkanes 2 and 3 were prepared in good yields by the treatment of 1,ω-bis-(1-tosylamidrazone)alkanes 1 with two molar equivalents of phosphoryl trichloride and phenylphosphonic dichloride, respectively. All the newly synthesized compounds were characterized by IR, (1) H NMR, (13) C NMR, (31) P NMR, and elemental analysis. All the new compounds were screened for their inhibitory effect on the key enzymes related to diabetes and obesity, as α-amylase and lipase. The in vitro study revealed that these alkane derivatives exert an inhibitory action against these key enzymes, especially 2b with an IC50 of 16 μg/mL against α-amylase and lipase. Overall, the findings of the current study indicate that 2d exhibits attractive properties and can therefore be considered for future application in the development of antidiabetic and hypolipidemic drugs.

Nonspecific Energy Expenditure of the Body and Body Mass Regulation

“…Inhibitors of digestive enzymes have been used for a long time as medicines in the treatment of severe forms of obesity to create artificial malabsorption of nutrients. This approach to the treatment of obesity continues to develop actively [13][14][15][16][17]. Disclosure of the detailed mechanism of the development of obesity, associated with energy metabolism disorders at this stage, requires the description of the role of various hormones, not only those produced by the "classical" endocrine glands, but also by cells of the gastrointestinal tract, liver, adipose tissue, various parts of the brain, muscles and other tissues.…”

Design, synthesis and biological evaluation of N‐substituted indole‐thiazolidinedione analogues as potential pancreatic lipase inhibitors

“…Past research has demonstrated the importance of five‐membered nitrogen heterocycles on PL inhibitory profiles. For instance, oxadiazole (Point et al., 2012), 1,2,4‐triazole (Bekircan et al., 2014; Kahveci et al., 2017), triaza‐phospholinoalkanes (Hamzaoui et al., 2015), rhodanine (Chauhan et al., 2019), thiazolidinedione (Sridhar, Bhurta, et al., 2017) etc. have explored for PL inhibition.…”